CLINICAL TRIALS PROFILE FOR SAIZEN

All Clinical Trials for SAIZEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00209235 ↗	Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments	Recruiting	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2003-01-01	We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
NCT00209235 ↗	Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments	Recruiting	Johns Hopkins University	Phase 2/Phase 3	2003-01-01	We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
NCT00209235 ↗	Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments	Recruiting	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Phase 2/Phase 3	2003-01-01	We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864

Clinical Trial Conditions for SAIZEN

Condition Name

Condition Name for SAIZEN
Intervention	Trials
Growth Hormone Deficiency	3
Infant, Small for Gestational Age	2
Infertility	2

Condition MeSH

Condition MeSH for SAIZEN
Intervention	Trials
Dwarfism, Pituitary	6
Dwarfism	5
Endocrine System Diseases	4

Clinical Trial Locations for SAIZEN

Trials by Country

Trials by Country for SAIZEN
Location	Trials
Australia	4
France	4
Canada	4
United States	3
Italy	2

Trials by US State

Trials by US State for SAIZEN
Location	Trials
New York	1
Massachusetts	1
Maryland	1

Clinical Trial Progress for SAIZEN

Clinical Trial Phase

Clinical Trial Phase for SAIZEN
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	6
Phase 3	6

Clinical Trial Status

Clinical Trial Status for SAIZEN
Clinical Trial Phase	Trials
Completed	13
Terminated	2
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for SAIZEN

Sponsor Name

Sponsor Name for SAIZEN
Sponsor	Trials
Merck KGaA, Darmstadt, Germany	11
Merck KGaA	10
EMD Serono	3

Sponsor Type

Sponsor Type for SAIZEN
Sponsor	Trials
Industry	32
Other	9
NIH	1

Last updated: April 27, 2026

Saizen (somatropin) Clinical Trials Update, Market Analysis, and Projection (2026 Outlook)

What is Saizen and what product formats matter for market sizing?

Saizen is a recombinant human growth hormone (rhGH) indicated for pediatric growth disorders and adult GH deficiency. The commercial value is driven by (1) label penetration across approved indications, (2) delivery format (notably injection vs. longer-interval formulations where applicable), and (3) competitive pressure from biosimilars.

From an IP and development standpoint, Saizen’s core “platform” is somatropin (biologic). Market access and volume are therefore shaped by biosimilar competition and payer contracting, not new molecule innovation.

Key commercial identifier used in market datasets

• INN/active: somatropin (rhGH)
• Brands (reference point): Saizen (Merck Serono history; Merck KGaA now via business units and licensing structures depending on geography)

What do clinical trial pipelines for Saizen look like in 2024-2026 coverage?

A current “clinical trials update” for the brand name “Saizen” is typically not a stand-alone category in registries because most growth-hormone programs are registered by INN (somatropin) rather than by the legacy brand, and because long-established bios remain on post-authorization studies rather than new Phase 3 filings.

Based on typical industry patterns for established rhGH products, the remaining trial activity for Saizen-linked programs concentrates in:

• Pediatric label support (dose optimization, adherence, real-world outcomes)
• Safety follow-up (long-term risk monitoring in treated cohorts)
• Switching and handling studies (conversion between injection regimens or delivery devices within the same active)

Execution reality for investors: treat “Saizen clinical trials” as an evidence-maintenance stream rather than a development-led growth engine, unless a specific registry entry for a Saizen-branded product shows otherwise.

Clinical-development implication for forecasting

• Near-term growth is less likely to come from new Phase 3 readouts.
• Growth is more likely to come from (a) switching dynamics within payer formularies, (b) biosimilar price erosion and retention, and (c) geography-specific tender cycles.

How does biosimilar competition change the Saizen market outlook?

rhGH is a biologic class with substantial biosimilar penetration in major markets. The practical forecasting model is therefore:

• Base demand is anchored to incidence/prevalence of GH deficiency and pediatric growth hormone indications.
• Brand share erodes under tender pressure and substitution.
• Revenues depend on net price more than on incremental patient numbers.

Market-shaping mechanisms

• Automatic substitution and tendering in EU-style tender markets
• Formulary preferencing and rebate-driven contracting in the US
• Geographic switching where biosimilars reach maturity earlier in certain countries
• Patient adherence and device preferences influencing non-medical switching

What is the market analysis framework for Saizen (sizing and drivers)?

A workable projection approach for Saizen uses three blocks: demand, share, and price.

1) Demand pool

The demand pool comes from treated populations with GH deficiency and related pediatric indications (e.g., idiopathic short stature, growth failure syndromes, Turner syndrome-related growth failure, and other label segments depending on country). The overall market is mature; elasticity is low.

2) Share

Share is the key variable post-2020:

• Brand share declines as biosimilars gain formulary access.
• Share can stabilize if the brand retains differentiation in specific devices, reimbursement arrangements, or clinician preference.

3) Net price

Net price typically tracks:

• list price changes minus discounting,
• tender wins (for competing biosimilars),
• payer pressure and volume commitments.

Market projection: what to expect through 2030

Because Saizen is a legacy rhGH brand, the base case is not a “compound annual growth” story driven by new indication launches. The market is mature and commoditizing.

Base case projection logic (2026-2030)

• Volume: flattish to low growth (treated population growth offset by substitution and therapy practice trends).
• Net revenue: declines in most markets due to sustained price erosion.
• Survivorship: brand revenues persist where contracts delay substitution or where device-level preference supports retention.

Scenario table (directional)

Scenario (2026-2030)	Volume Trend	Net Price Trend	Revenue Trend
Downside	Slight decline	Faster erosion	Material decline
Base case	Flat	Continued erosion	Moderate decline
Upside	Flat to slight growth	Slower erosion via contracting	Stable to slight growth

Where does upside come from if Saizen is mature?

Upside usually comes from non-clinical levers:

• Contracting protection in specific geographies or large tenders
• Device and administration experience that reduces switching friction
• Treatment continuity in chronic pediatric care pathways

What is the patent and market-exclusivity posture for Saizen?

For established somatropin products, exclusivity typically hinges on:

• initial peptide/bio-manufacturing protection (legacy),
• formulation/device IP,
• region-specific biosimilar entry timing.

For brand-level planning, the main commercial risk is not “blocking” competitors but absorbing price erosion after biosimilar maturation.

Investor takeaway: for Saizen, expect revenue to be governed primarily by market access and competitive intensity, not by new exclusivity extensions.

Clinical trials update: how to interpret registry activity for Saizen in an investment model

For a mature rhGH brand:

• Phase 1-2: rarely changes commercial trajectory unless it unlocks a meaningful label expansion.
• Phase 3: uncommon without new delivery systems, new dosing, or new patient selection.
• Post-marketing: supports safety and switching/regimen compliance but generally does not reverse pricing pressure.

What near-term catalysts should be treated as “signal,” not noise?

In rhGH, the only catalysts that materially move forecasting are:

• Regulatory label expansions (new subpopulation approvals)
• Major tender wins/losses in large markets
• Significant device or formulation changes that affect adherence and payer preference

Key Takeaways

• Saizen is a mature rhGH brand where commercial performance depends on biosimilar competition and payer contracting, not new clinical development.
• Clinical trial activity, where present, is typically evidence maintenance rather than a Phase 3-led growth driver.
• Market projections to 2030 follow a base-demand with declining net price pattern, yielding flat-to-negative revenue direction in most markets.
• Actionable forecast lever: model share and net price under tender/contract scenarios; treat volume as comparatively stable.

---

FAQs

1) Is Saizen expected to launch new Phase 3 pivotal trials that drive revenue growth?

No consistent pattern indicates a Phase 3 catalyst that reverses mature-market pricing pressure. Forecasts should assume maintenance-level clinical work rather than brand-new label expansion.

2) What is the main risk to Saizen revenue between 2026 and 2030?

Sustained biosimilar-driven net price erosion through payer substitution and tendering.

3) What are the most important drivers of Saizen market share?

Formulary status, tender outcomes, rebate design, and device or administration preference that reduces switching.

4) Does pediatric demand growth offset competitive price pressure?

Usually not. The demand pool grows slowly relative to the speed of price compression in commoditizing biologics.

5) What would represent an upside catalyst for the brand?

A regionally significant contracting position (delayed substitution, managed access) or a clear regulatory label expansion tied to reimbursement.

---

References

[1] APA citation placeholder: No sources were provided in the prompt to cite.